7-(3-amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid | 112811-60-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-(3-amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
• 英文别名: 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-amino-1-pyrrolidinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid；7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid；3-Quinolinecarboxylic acid, 1,4-dihydro-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-；7-(3-aminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
• CAS: 112811-60-6
• 化学式: C₁₈H₂₀FN₃O₄
• 分子量: 361.373
• InChiKey: DWUDIDPUESEORN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  96.1
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  7-(3-amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 、 丙烯腈 以 甲醇 为溶剂， 反应 36.0h， 以95%的产率得到7-[3-(2-cyano-ethylamino)-pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
  参考文献：
  名称：

  [EN] QUINOLONE ANTIBACTERIAL AGENTS
  [FR] AGENTS ANTIBACTERIENS A LA QUINOLONE

  摘要：

  式(I)的化合物中，其中A是式(II)，式(III)或式(IV)，B是式(V)，式(VI)或式(VII)，可用于各种应用，包括用作抗菌剂。

  公开号：

  WO2005049602A1
• 作为产物：
  描述：

  1-cyclopropyl-6-fluoro-8-methoxy-7-(3-t-butoxycarbonylaminopyrrolidin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 生成 7-(3-amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
  参考文献：
  名称：

  8-alkoxyquinolonecarboxylic acid and salts thereof

  摘要：

  喹诺酮羧酸衍生物的化学式如下：##STR1## 其中 R 表示氢原子或较低的烷基基团，R.sup.1 表示较低的烷基基团，R.sup.2 表示氢原子、氨基团或硝基团，X 表示卤素原子，Z 表示卤素原子、哌嗪基团、N-甲基哌嗪基团、3-甲基哌嗪基团、3-羟基吡咯啉基团或吡咯啉基团，如下所示：##STR2##（这里，n 为 0 或 1，R.sup.3 表示氢原子或较低的烷基基团，R.sup.4 表示氢原子、较低的烷基基团，R.sup.5 表示氢原子、较低的烷基基团、酰基基团或烷氧羰基基团），其水合物和药学上可接受的盐被用作抗菌剂。

  公开号：

  US04980470A1

文献信息

• [EN] RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES<br/>[FR] DERIVES DE RIFAMYCINE IMINO EFFICACES CONTRES DES MICROBES PHARMACORESISTANTS
  申请人：CUMBRE INC

  公开号：WO2005070941A1

  公开（公告）日：2005-08-04

  The present invention relates to rifamycin 3-iminomethylenyl (-CH=N-) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (-CH=N-) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

  本发明涉及具有抗微生物活性的利福霉素3-亚甲基亚胺基(-CH=N-)衍生物，包括对耐药微生物的活性。所述的利福霉素衍生物具有一个利福霉素基团，通过亚甲基亚胺基(-CH=N-)在利福霉素基团的C-3碳上与一个连接剂共价连接，而连接剂又与DNA旋转酶和拓扑异构酶IV抑制剂家族中的奎诺酮结构或其药效团共价连接。这种创新的利福霉素是新颖的，并对利福平和环丙沙星耐药微生物表现出活性。
• C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
  申请人：Combrink Keith

  公开号：US20050256096A1

  公开（公告）日：2005-11-17

  Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to C-25 carbamate derivatives of rifamycin having another functional group or pharmacophore covalently attached to this position through a carbamate linkage. The resulting compounds exert their antimicrobial activity through a dual-function mechanism and therefore exhibit reduced frequency of resistance.

  当前发明的化合物涉及具有抗微生物活性的利福霉素衍生物，包括针对耐药微生物的活性。更具体地说，当前发明的化合物涉及利福霉素的C-25氨基甲酸酯衍生物，通过氨基甲酸酯键连接到该位置的另一个功能基团或药效团。由此产生的化合物通过双重功能机制发挥其抗微生物活性，因此表现出较低的抗药性频率。
• Rifamycin derivatives effective against drug-resistant microbes
  申请人：Ma Zhenkun

  公开号：US20050261262A1

  公开（公告）日：2005-11-24

  Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.

  本发明涉及具有抗微生物活性的利福霉素衍生物，包括对耐药微生物的活性。本发明的利福霉素衍生物独特地设计在于，它们具有利福霉素基团通过利福霉素基团的C-3碳与连接基团共价连接，并且连接基团进一步与治疗性基团或抗菌剂/药效团共价连接。治疗性基团可以是喹诺酮、噁唑烷酮、大环内酯、氨基糖苷、四环素核心或与抗菌剂相关的结构/药效团。
• Rifamycin imino derivatives effective against drug-resistant microbes
  申请人：Ding Z. Charles

  公开号：US20050209210A1

  公开（公告）日：2005-09-22

  The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

  本发明涉及具有抗微生物活性的利福霉素3-亚甲基亚胺基(—CH═N—)衍生物，包括对耐药微生物的活性。所述利福霉素衍生物具有利福霉素基团通过亚甲基亚胺基(—CH═N—)与连接基团共价连接于利福霉素基团的C-3碳，并且连接基团与DNA酶解酶和拓扑异构酶IV抑制剂家族中的喹诺酮结构或其药效团共价连接。本发明的利福霉素是新颖的，并且对利福平和环丙沙星耐药微生物均有活性。
• Quinoline-3-carboxylic acid derivatives, their preparation and use
  申请人：Sankyo Company Limited

  公开号：EP0241206A2

  公开（公告）日：1987-10-14

  Compounds of formula (I): (in which R1 is alkoxy, R is alkyl, haloalkyl, alkylammo, cycloalkyl or optionally substituted phenyl, X is chlorine or fluorine and Y is selected from certain specific heterocycles) have excellent antibacterial activity. They may be prepared by introducing the group represented by Y into the corresponding compound in which Y is replaced by a halogen atom.

  式(I)化合物： (其中 R1 为烷氧基，R 为烷基、卤代烷基、烷基酰胺基、环烷基或任选取代的苯基，X 为氯或氟，Y 选自某些特定杂环）具有极佳的抗菌活性。它们可以通过将 Y 所代表的基团引入相应的化合物中来制备，其中 Y 被卤素原子取代。